0000000000075292

AUTHOR

Pierre-marie Girard

showing 4 related works from this author

Anti- Toxoplasma Activities of 24 Quinolones and Fluoroquinolones In Vitro: Prediction of Activity by Molecular Topology and Virtual Computational Te…

2000

ABSTRACT The apicoplast, a plastid-like organelle of Toxoplasma gondii , is thought to be a unique drug target for quinolones. In this study, we assessed the in vitro activity of quinolones against T. gondii and developed new quantitative structure-activity relationship models able to predict this activity. The anti- Toxoplasma activities of 24 quinolones were examined by means of linear discriminant analysis (LDA) using topological indices as structural descriptors. In parallel, in vitro 50% inhibitory concentrations (IC 50 s) were determined in tissue culture. A multilinear regression (MLR) analysis was then performed to establish a model capable of classifying quinolones by in vitro acti…

medicine.drug_classStereochemistryMolecular ConformationBiologyModels BiologicalStructure-Activity RelationshipAnti-Infective AgentsPredictive Value of TestsMoxifloxacinparasitic diseasesmedicineAnimalsStructure–activity relationshipComputer SimulationPharmacology (medical)Mechanisms of Action: Physiological EffectsAntibacterial agentPharmacology4-QuinolonesBiological activityQuinoloneGatifloxacinGrepafloxacinTrovafloxacinInfectious DiseasesRegression AnalysisToxoplasmaFluoroquinolonesmedicine.drugAntimicrobial Agents and Chemotherapy
researchProduct

Grazoprevir/elbasvir for the immediate treatment of recently acquired HCV genotype 1 or 4 infection in MSM.

2020

Abstract Background In Europe, increases in HCV infection have been observed over the last two decades in MSM, making them a key population for recently acquired HCV. Alternative combinations of direct-acting antiviral agents against early HCV infection need to be assessed. Patients and methods In this pilot trial, MSM with recently acquired genotype 1 or 4 HCV infection were prospectively included and received 8 weeks of oral grazoprevir 100 mg and elbasvir 50 mg in a fixed-dose combination administered once daily. The primary endpoint was sustained virological response evaluated 12 weeks after the end of treatment (EOT) (SVR12). Secondary endpoints were the virological characterization of…

hepatitis C virusCyclopropanesMaleadverse eventmen who have sex with menHepacivirusmedicine.disease_causeSexual and Gender Minoritiesblood HIV RNA0302 clinical medicine[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesfollow-upClinical endpointMedicinePharmacology (medical)infections030212 general & internal medicinehepatitis ceducation.field_of_studySulfonamideshepatitis c rnaImidazolesvirus diseasesHepatitis Cvirologyhepatitis C virus genotype 13. Good healthEuropeInfectious DiseasesGrazoprevirRNA Viral030211 gastroenterology & hepatologyDrug Therapy CombinationMicrobiology (medical)medicine.medical_specialtyElbasvirGenotypeHepatitis C virusPopulationelbasvirAntiviral Agentsreinfection03 medical and health sciencesInternal medicineQuinoxalinesHumansHomosexuality MaleAdverse effecteducationplasmasuicideBenzofuransPharmacologybusiness.industrySurrogate endpointHIVgrazoprevirHepatitis C Chronicmedicine.diseaseAmidessurrogate endpoints[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/PharmacologyQuality of LifeCarbamatesbusinessThe Journal of antimicrobial chemotherapy
researchProduct

Intensification with pegylated interferon during treatment with tenofovir in HIV-hepatitis B virus co-infected patients

2016

International audience; In hepatitis B “e” antigen (HBeAg) positive patients with hepatitis B virus (HBV) mono-infection, intensification of nucleos(t)ide analogue treatment with pegylated interferon (PegIFN) could help induce higher HBeAg seroclearance rates. Our aim was to determine the long-term effect of adding PegIFN to tenofovir (TDF)-containing antiretroviral therapy on seroclearance in HBeAg-positive patients co-infected with the human immunodeficiency virus (HIV) and HBV. In this prospective matched cohort study, 46 patients with 1-year PegIFN intensification during TDF-containing antiretroviral therapy (TDF+PegIFN) were matched 1:1 to controls undergoing TDF without PegIFN (TDF) u…

AdultMaleHBsAgmedicine.medical_specialtyCirrhosisTenofovirmedicine.disease_causeAntiviral Agents[ SDV.MP.VIR ] Life Sciences [q-bio]/Microbiology and Parasitology/VirologyGastroenterology03 medical and health sciencesHepatitis B Chronic0302 clinical medicinePegylated interferonVirologyInternal medicinemedicineHumansHepatitis B e AntigensLongitudinal StudiesProspective Studies030212 general & internal medicineTenofovirProspective cohort studyHepatitis B virusHepatologybusiness.industryvirus diseasesMiddle AgedHepatitis Bmedicine.diseasedigestive system diseases3. Good healthTreatment OutcomeInfectious DiseasesHBeAgImmunology[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/VirologyFemale030211 gastroenterology & hepatologyInterferonsbusinessmedicine.drug
researchProduct

Prediction of quinolone activity against Mycobacterium avium by molecular topology and virtual computational screening.

2000

ABSTRACT We conducted a quantitative structure-activity relationship study using a database of 158 quinolones previously tested against Mycobacterium avium-M. intracellulare complex in order to develop a model capable of predicting the activity of new quinolones against the M. avium-M. intracellulare complex in vitro. Topological indices were used as structural descriptors and were related to anti- M. avium-M. intracellulare complex activity by using the linear discriminant analysis (LDA) statistical technique. The discriminant equation thus obtained correctly classified 137 of the 158 quinolones, including 37 of a test group of 44 randomly chosen compounds. This model was then applied to 2…

medicine.drug_classStereochemistryComputational biologyModels BiologicalStructure-Activity RelationshipAnti-Infective AgentsMoxifloxacinPredictive Value of TestsmedicinePharmacology (medical)Computer SimulationMechanisms of Action: Physiological EffectsAntibacterial agentPharmacology4-QuinolonesbiologyLinear discriminant analysisbiology.organism_classificationQuinoloneMycobacterium avium ComplexGatifloxacinInfectious DiseasesSparfloxacinMolecular topologymedicine.drugMycobacteriumAntimicrobial agents and chemotherapy
researchProduct